source
- Eli Lilly stops disclosing Phase 1 pipeline, making early-stage projects invisible in earnings decksEli Lilly has become more opaque as its size grows, choosing to stop public disclosure of its early-stage research efforts. The shift was noted earlier this year when the company removed Phase 1 pr…
- Replimune to file third FDA application for RP1 cancer therapy after productive talksReplimune announced it will submit a third marketing application for its experimental cancer therapy RP1, following what the company described as productive discussions with the Food and Drug Admin…